VRCAStockVerrica Pharmaceuticals Inc
Verdicts genuinely change. Free email alert the moment VRCA's does — no target price to set, unlike "Alert" above.
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Trade plan
Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
Verrica Pharmaceuticals Inc (VRCA) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-12). See the full ratio breakdown and business-activity screen below for the reasoning.
This sits among 451 compliant Healthcare stocks we track. See compliant Healthcare stocks →
🕌 In-house Compliance Research
Computed from published company financials, balance sheet as of 2026-06-30. These ratios come from the issuer's own published statements rather than structured SEC data.
Business activity: not screened
We have not screened this company's line of business, so these ratios say nothing about whether what it does is permissible.
AAOIFI Unverified⚠️ debt implausibly low vs. real finance costs 3 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.46% | 30.00% | Pass |
| Interest-bearing investments | 12.78% | 30.00% | Pass |
| Non-permissible income | 2.61% | 5.00% | Pass |
Usmani Unverified⚠️ debt implausibly low vs. real finance costs 4 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 5.03% | 33.00% | Pass |
| Interest-bearing investments | 31.82% | 33.00% | Pass |
| Non-liquid assets | 37.81% | at least 20.00% | Pass |
| Non-permissible income | 2.61% | 5.00% | Pass |
MSCI Fail 3 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 1.16% | 33.33% | Pass |
| Cash + interest-bearing securities | 31.82% | 33.33% | Pass |
| Accounts receivable | 62.19% | 33.33% | Fail |
| Non-permissible income | 2.61% | 5.00% | Pass |
FTSE Fail 3 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.33% | Pass |
| Cash + interest-bearing securities | 31.82% | 33.33% | Pass |
| Accounts receivable | 62.19% | 50.00% | Fail |
| Non-permissible income | 2.61% | 5.00% | Pass |
Dow Jones Islamic Market Unverified⚠️ debt implausibly low vs. real finance costs 4 of 4 ratios pass
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.39% | 33.00% | Pass |
| Cash + interest-bearing securities | 10.66% | 33.00% | Pass |
| Accounts receivable | 10.17% | 33.00% | Pass |
| Non-permissible income | 2.61% | 5.00% | Pass |
S&P Shariah Unverified⚠️ debt implausibly low vs. real finance costs 4 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.23% | 33.00% | Pass |
| Cash + interest-bearing securities | 6.25% | 49.00% | Pass |
| Accounts receivable | 5.96% | 49.00% | Pass |
| Non-permissible income | 2.61% | 5.00% | Pass |
MSCI M-Series Unverified⚠️ debt implausibly low vs. real finance costs 4 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.23% | 33.33% | Pass |
| Cash + interest-bearing securities | 6.25% | 33.33% | Pass |
| Accounts receivable | 12.21% | 49.00% | Pass |
| Non-permissible income | 2.61% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
How close is it to flipping?
Every current reading against its own line, closest first. A verdict is only as durable as that distance.
The numbers the ratios are built from
Read from VRCA's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | $35.6M | 2025-12-31 | Revenues |
| Interest-bearing debtShort and long-term borrowings | $0 | 2026-06-30 | LongTermDebt (stale, beyond normal quarterly tolerance), LongTermDebtCurrent (stale, beyond normal quarterly tolerance) |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $11.5M | 2026-06-30 | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents |
| Total assetsBalance sheet total | $36.0M | 2026-06-30 | Assets |
| Market capDenominator for AAOIFI | $89.7M | live quote | price x shares |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | $122.4M | 756 trading days | closes x shares |
| 24-month average market capDenominator for Dow Jones Islamic Market | $64.8M | 504 trading days | closes x shares |
| Non-permissible revenueInterest and excluded income | $929.0K | 2025-12-31 | InvestmentIncomeInterest |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
What changed, and when
Verdict history for VRCA. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
- 2026-09-07 No change recorded No verdict change for VRCA has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.
ℹ️ no compliance scan has run for 3 days - this is not a reading of today
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 40.50 | NEUTRAL |
| Stochastic %K (14) | 26.29 | NEUTRAL |
| CCI (20) | -64.53 | NEUTRAL |
| Williams %R (14) | -73.71 | NEUTRAL |
| MACD (12,26,9) | 0.02 | BUY |
| ROC (10) | -4.82 | SELL |
| Momentum (10) | -0.18 | SELL |
| EMA (10) | 3.44 | BUY |
| SMA (10) | 3.45 | BUY |
| EMA (20) | 3.64 | SELL |
| SMA (20) | 3.60 | SELL |
| EMA (30) | 3.83 | SELL |
| SMA (30) | 3.87 | SELL |
| EMA (50) | 4.16 | SELL |
| SMA (50) | 4.31 | SELL |
| EMA (100) | 4.73 | SELL |
| SMA (100) | 4.93 | SELL |
| EMA (200) | 5.40 | SELL |
| SMA (200) | 5.54 | SELL |
About Verrica Pharmaceuticals Inc
Healthcare · Biotechnology
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Background via Yahoo Finance — informational, not part of the verdict.
Latest Signal — 2026-08-28
Stop 4.96 Now 3.46 Target 5.29
⚪ NEUTRAL — No Edge
Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.
Scores: 2 bullish / 2 bearish
Average — needs more confirmation before sizing up
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 42 |
| 🕐 1H | BEARISH | 50 |
| ⏱ 15-Min | RANGING | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is this a fatwa?
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Why can the standards disagree?
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
How often is this re-screened?
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
Do I need to purify dividends?
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-10-27 · Asset managers net 923449 (+22072)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.